Zevra Therapeutics, Inc. ZVRA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.1%+1.6pp | 84.5%+3.9pp | 80.7%+8.7pp | 72%-6.9pp | 78.8%+10.3pp | |
| Net margin | 101.6%+23.4pp | 78.2%+36.3pp | 41.9%+37.6pp | 4.3%+231pp | -226.6%+220pp | |
| EBITDA margin | 2.2%+52.5pp | -50.3%+47.2pp | -97.6%+83.9pp | -181.5%-20.3pp | -161.1%+180pp | |
| Returns | ||||||
| Return on equity | 100.7%+15.0pp | 85.7%+50.8pp | 34.8%+31.3pp | 3.5%+208pp | -204.8%+3.1pp | |
| Return on assets | 55.1%+19.1pp | 36%+20.7pp | 15.3%+14.0pp | 1.3%+58.1pp | -56.8%+3.4pp | |
| Return on invested capital | -0.1%+49.8pp | -49.9%+3.2pp | -53.2%+11.4pp | -64.6%+120pp | -184.7%+6.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.5×+0.1× | 0.4×+0.1× | 0.3×+0.1× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.9×-0.8× | 5.7×-2.9× | 8.6×+0.8× | 7.9×+4.8× | 3×+0.5× | |
| Quick ratio | 4.9×-0.8× | 5.7×-2.9× | 8.6×+0.8× | 7.8×+5.2× | 2.6×+0.4× | |
| Cash ratio | 2×+0.4× | 1.6×-0.5× | 2.1×+0.4× | 1.7×+0.3× | 1.4×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.4× | 0.4×-0.1× | 0.5×-0.1× | 0.5×-1.0× | 1.5×0.0× | |
| Debt-to-assets | 0×-0.2× | 0.2×0.0× | 0.2×0.0× | 0.2×-0.1× | 0.4×0.0× | |
| Net debt / EBITDA | -35.8×— | —— | —— | —— | —— | |
| Interest coverage | -0×+7.2× | -7.2×+3.4× | -10.7×+3.4× | -14×-5.7× | -8.4×+3.5× | |
| Per Share | ||||||
| Book value per share | $3.42+26.5% | $2.70+13.5% | $2.38+14.4% | $2.08+174% | $0.76-11.6% | |
| Valuation | ||||||
| Market capitalization | $773.23M+58.2% | $504.43M-5.5% | $533.84M+6.7% | $500.32M+23.4% | $405.33M-8.9% | |
| Enterprise value | $678.78M+32.5% | $505.23M-6.8% | $542.12M+5.3% | $514.88M+19.8% | $429.82M-8.9% | |
| Price / earnings | 6.2×— | 6.1×-9.1× | 15.1×-174× | 189.2×— | —— | |
| Price / sales | 6.3×-5.7× | 4.7×-1.6× | 6.3×-1.7× | 8.1×-1.9× | 10×-8.9× | |
| Price / book | 3.8×-8.2× | 3.3×-0.7× | 4×-0.3× | 4.3×-5.6× | 9.9×-1.3× | |
| EV / EBITDA | 260.8×— | —— | —— | —— | —— | |
| EV / sales | 5.6×-7.2× | 4.7×-1.7× | 6.4×-1.9× | 8.3×-2.3× | 10.6×-9.4× | |
| Earnings yield | 15.9%+34.5pp | 16.5%+9.9pp | 6.6%+6.1pp | 0.5%+23.2pp | -22.7%+1.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Zevra Therapeutics, Inc. (ZVRA) runs a 86.1% gross margin and a -103.9% operating margin, with a 101.6% net margin.
- Where do Zevra Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Zevra Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
